비르 바이오테크 (VIR)

Shares of Vir Biotechnology were down 44.90% on Thursday after the company announced phase 2 trial results for an influenza A therapy candidate. Vir announced that VIR-2482 failed to meet efficacy endpoints in a phase 2 trial for treating influenza A. The highest dose showed a non-statistically significant 16% reduction in illness. Disappointingly, VIR-2842 is the company's sole wholly owned candidate.

https://www.fool.com/investing/2023/07/20/why-shares-of-vir-biotechnology-are-plunging-thurs/?source=eptyholnk0000202&utm_source=yahoo-host&utm_medium=feed&utm_campaign=article